Sponsors (2)
The bill seeks to speed access to OTC topical medicines and sunscreen ingredients, reduce animal testing, and increase transparency, but it trades off higher reliance on real‑world evidence, potential privacy risks, new costs for sponsors, constraints on FDA flexibility, and added administrative burden that could affect safety and market certainty.
All sunscreen users and the general public retain access to historically used sunscreens because FDA must consider prior safety data and the role of broad‑spectrum SPF≥15 when issuing orders.
Patients and OTC topical product consumers could get faster access to new topical medicines and sunscreen ingredients because the bill allows use of real‑world evidence and encourages alternative non‑animal test methods to supplement trials.
Scientists, researchers, and sponsors gain clearer, more predictable regulatory pathways because the bill promotes non‑animal alternative tests and requires draft guidance within a year on acceptable evidence and testing approaches.
Patients and consumers could face increased safety risk because allowing real‑world evidence to supplement trials may lower evidentiary standards and enable approvals based on weaker safety data.
Individuals whose health data are reused could face privacy and data‑quality risks because expanded use of real‑world data raises safeguards and reuse concerns.
Small businesses and sponsors may incur higher costs because generating valid real‑world evidence and adopting new nonclinical methods requires investment and could be a barrier for smaller firms.
Based on analysis of 4 sections of legislative text.
Introduced July 29, 2025 by Margaret Wood Hassan · Last progress July 29, 2025
Requires the Department of Health and Human Services/FDA to accept real‑world evidence alongside traditional clinical trials when evaluating nonprescription topical drug active ingredients, while preserving FDA’s authority to weigh benefits and risks. Directs FDA to consider specified nonclinical, non‑animal test methods for topical products, issue draft guidance on alternatives to animal testing within one year, and apply consistent evidence standards to sunscreen active ingredients. Also requires that any final FDA order on sunscreen active ingredients account for historical safety data and the role of broad‑spectrum SPF 15+ sunscreens in skin cancer prevention. Mandates periodic reports to Congress on implementation and progress (first report within 18 months, then annually for five years) and public posting of those reports on the FDA website within seven days of submission to key congressional committees.